Did Gilead Sciences Make an $11 Billion Blunder?

I read an interesting article recently about Gilead Sciences (NASDAQ:GILD). Bloomberg Opinion columnist Joe Nocera summarized Gilead's quest to market drugs that cure hepatitis C. The author did a great job explaining the unique challenges for Gilead and the entire biopharmaceutical industry in developing products that cure rather than just treat diseases.